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Abstract 
Background: Sugammadex (SGX) is a modified γ‑cyclodextrin used for reversal of steroidal neuromuscular blocking 
agents during general anesthesia. Despite its application in clinical use, whether SGX treatment exerts any effects on 
membrane ion currents in neurons remains largely unclear. In this study, effects of SGX treatment on ion currents, par‑
ticularly on delayed‑rectifier K+ current [IK(DR)], were extensively investigated in differentiated NSC‑34 neuronal cells.
Results: After cells were exposed to SGX (30 μM), there was a reduction in the amplitude of IK(DR) followed by an 
apparent slowing in current activation in response to membrane depolarization. The challenge of cells with SGX 
produced a depolarized shift by 15 mV in the activation curve of IK(DR) accompanied by increased gating charge of this 
current. However, the inactivation curve of IK(DR) remained unchanged following SGX treatment, as compared with 
that in untreated cells. According to a minimal reaction scheme, the lengthening of activation time constant of IK(DR) 
caused by cell treatment with different SGX concentrations was quantitatively estimated with a dissociation constant 
of 17.5 μM, a value that is clinically achievable. Accumulative slowing in IK(DR) activation elicited by repetitive stimuli 
was enhanced in SGX‑treated cells. SGX treatment did not alter the amplitude of voltage‑gated Na+ currents. In SGX‑
treated cells, dexamethasone (30 μM), a synthetic glucocorticoid, produced little or no effect on L‑type Ca2+ currents, 
although it effectively suppressed the amplitude of this current in untreated cells.
Conclusions: The treatment of SGX may influence the amplitude and gating of IK(DR) and its actions could potentially 
contribute to functional activities of motor neurons if similar results were found in vivo.
Keywords: Sugammadex, Motor neuron, Delayed‑rectifier K+ current, Activation kinetics, L‑type Ca2+ current, 
Glucocorticoid
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Background
Sugammadex (SGX) is recognized as a modified 
γ-cyclodextrin with a lipophilic core and a hydrophilic 
periphery, and it has been used clinically for reversal 
of neuromuscular blockade caused by rocuronium or 
vecuronium during general anesthesia [1–5]. A previous 
report showed that addition of SGX could cause neu-
ronal apoptosis in primary cultures [6]. This compound 
per se was also reported to be effective at reversing neu-
rodegenerative disorder of the lower motor neurons [7, 
8]. However, interestingly, how the treatment with SGX 
can perturb ionic currents remains largely unexplored.
The KV3 channels, a subfamily of KV channels, are dis-
tinguished from other types of KV channels by more posi-
tively shifted voltage-dependent activation and by faster 
activation and deactivation rates [9, 10]. These differ-
ences enable KV3 channels to be major determinants of 
high-frequency firing existing in several types of central 
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neurons [11–15]. The activity of KV3.1 channels has been 
recently described as playing a crucial role in control-
ling the amplitude of action potentials at synapses [16]. 
The de novo mutations in KCNC1, which encodes KV3.1 
channels, have been also found to expand phenotypic 
spectra of this channel to progressive myoclonus epilepsy 
[17]. Therefore, these channels clearly are important tar-
gets used for investigations on electrical behaviors of 
central neurons including motor neurons [10].
The NSC-34 mouse motor neuron cell line is a hybri-
doma cell line derived from the fusion of mouse neu-
roblastoma with motor neuron-enriched spinal cord 
cells [18, 19]. These cells may create an easily accessible 
and clonally uniform motor neuron-like cell line that 
overcomes the problems associated with the culturing 
of primary spinal motor neurons. It has been demon-
strated to be a suitable model for investigations on the 
mechanisms of neuronal development and differentiation 
in  vitro and for studying electrophysiological properties 
of motor neurons in spite of being not considered as an 
adult motor neuron [18–20]. The biophysical properties 
of delayed-rectifier K+ current [IK(DR)] in NSC-34 cells 
were previously found to resemble the KV3.1-encoded 
current because of positive mRNA detection of KV3.1 
(KCNC1) [21, 22]. As NSC-34 cells were differentiated, 
the density of IK(DR) was significantly enhanced. Previ-
ous work from our laboratory has shown that removal of 
membrane cholesterol by methyl-β-cyclodextrin, a cyclic 
oligosaccharide, could modify activation kinetics of IK(DR) 
in motor neuron-like cells [23]. Additionally, although 
voltage-gated Na+ current (INa) in NSC-34 neuronal cells 
has been previously reported [24], few studies have been 
concerned with the biophysical or pharmacological prop-
erties of Ca2+ currents in these cells.
Therefore, the purpose of this work was to test whether 
SGX treatment could exert any perturbations on ionic 
currents present in NSC-34 neuronal cells differentiated 
with low serum and retinoic acid. The biophysical and 
pharmacological properties of ionic currents including 
delayed-rectifier K+ current [IK(DR)], voltage-gated Na+ 
current (INa) and L-type Ca2+ current (ICa,L) in untreated 
and SGX-treated cells have been characterized and com-
pared in this study. Interestingly, the present results 
indicate that SGX treatment is capable of modifying the 
activation kinetics of IK(DR) elicited by membrane depo-




Sugammadex (Bridion®, SGX, C72H104Na8O48S8) was 
obtained from Schering-Plough (Kenilworth, NJ, USA), 
aconitine, dexamethasone (DEX), l-aspartic acid, 
neostigmine, nifedipine, retinoic acid, tetraethylammo-
nium chloride (TEA) and tetrodotoxin were from Sigma-
Aldrich (St. Louis, MO, USA), iberiotoxin, apamin and 
ω-conotoxin GVIA were from Alomone Labs (Jerusa-
lem, Israel), isobavachalcone (2′,4′,4-trihydroxy-3′-[3″-
methylbut-3″-enyl]chalcone) was from Enzo Life Sci. 
(Plymouth Meeting, PA, USA), midazolam was from 
Nang Kuang Pharmaceutical Co. (Tainan City, Taiwan) 
and ranolazine [(±)-N-(2,6-dimethyl-phenyl)-4[2-hy-
droxy-3(2-methoxy-phenoxy)propyl]-1-piperazine aceta-
mide] was from Tocris Cookson, Ltd. (Bristol, UK). For 
cell preparations, all culture media, fetal bovine serum 
(FBS), l-glutamine, trypsin/EDTA, penicillin–strepto-
mycin and amphotericin B were obtained from Invitro-
gen (Carlsbad, CA, USA). All other chemicals including 
CdCl2, CsCl, CsOH and MgSO4 were obtained from 
regular commercial chemicals and of reagent grade. The 
compositions of bathing and pipette solutions used in 
this study are illustrated in Table 1.
Cell preparation and differentiation
NSC-34 neuronal cells were originally produced by fusion 
of the motor neuron-enriched, embryonic mouse spinal 
cords with the mouse neuroblastoma [19]. These cells 
were kindly provided by Professor Yuh-Jyh Jong (Depart-
ment of Pediatrics, Kaohsiung Medical University Hospi-
tal, Kaohsiung City, Taiwan). They were routinely grown 
in 1:1 mixture of Dulbecco’s modified Eagle medium 
(DMEM) and Ham’s F12 medium that was supplemented 
with 10% (v/v) FBS and 1% penicillin–streptomycin. Cul-
tures were incubated at 37  °C in a humidified environ-
ment of 5% CO2/95% air. The medium was replenished 
every 2–3 days for removal of non-adhering cells. To slow 
cell proliferation and enhance their maturation towards 
a differentiated state [20], before confluence, cells were 
grown in 1:1 DMEM plus Ham’s F12 medium supple-
mented with low serum (1% FBS) and 1 μM retinoic acid. 
The SGX-treated cells were incubated at 37 °C for 1 h in 
normal Tyrode’s solution containing different concentra-
tions of this compound. The reason that the duration was 
set at 1 h was to ensure that SGX could exert its interac-
tion with cell membrane.
Electrophysiological measurements
Shortly before each experiment, cells were dissociated, 
and an aliquot of cell suspension was transferred to a 
homemade recording chamber positioned on the stage 
of a CKX-41 inverted microscope (Olympus, Tokyo, 
Japan). Cells were immersed at room temperature (20–
25  °C) in normal Tyrode’s solution containing 1.8 mM 
CaCl2. The patch electrodes used were prepared from 
Kimax capillary tubes (#34500; Kimble Glass, Vineland, 
NJ, USA) using a vertical two-step electrode puller 
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(PP-83 or PP-830; Narishige, Tokyo, Japan), and their 
tips were then fire-polished with an MF-83 micro-forge 
(Narishige). Experiments were performed using the 
whole-cell configuration of standard patch-clamp tech-
nique using either an RK-400 (Bio-Logic, Claix, France) 
or an Axopatch 200B (Molecular Devices, Sunny-
vale, CA, USA) patch-clamp amplifier [19]. Junctional 
potentials that developed when the composition of 
the pipette solution was different from that in the bath 
were nulled.
Data recordings
The signals consisting of voltage and current tracings 
were displayed and recorded online using an ASUSPRO-
BU401LG computer (ASUS, Taipei City, Taiwan) equipped 
with a Digidata 1440A device (Molecular Devices), and 
the experiments were controlled by pCLAMP 10.2 soft-
ware (Molecular Devices). Current signals were low-pass 
filtered at 3 kHz and digitized at 10 kHz. In some experi-
ments of verifying analog-to-digital conversion, signals are 
digitized using a PowerLab acquisition system with Lab-
Chart 7.0 programs (AD Instruments, Gerin, Tainan City, 
Taiwan). The resultant data achieved during this experi-
ment were analyzed off-line by use of various analytical 
tools including the LabChart 7.0 program (Gerin), Origin 
8.0 (OriginLab, Northampton, MA, USA) and custom-
made macro procedures run under Excel 2013 (Microsoft, 
Redmond, WA, USA). The voltage-step profiles digitally 
created from pCLAMP 10.2 were employed to evaluate 
current–voltage (I–V) relationships or steady-state inacti-
vation of ionic currents [e.g., IK(DR)].
Data analyses
The relationships between the relative IK(DR) amplitude 
and the membrane potential obtained with or without 
the treatment of SGX (30 μM) were fitted with a Boltz-
mann function of the following form:
where Imax is the maximal amplitude of IK(DR) elicited by 










is half-maximal activation, q the apparent gating charge, 
F Faraday’s constant, R the universal gas constant, and T 
the absolute temperature.
The free energy involved in the gating of IK(DR) (ΔG0) 
was calculated assuming that there is a 2-state (i.e., 
closed [resting] and open) gating model inherently in the 
channel. ΔG0 for IK(DR) activation at 0 mV with or without 
treatment of SGX would be equal to q × F × V1/2 [25, 26]. 
The standard errors of ΔG0 (i.e., σqFV1/2) were calculated 
according to:
where σq and σV1/2 represent the standard errors in q and 
V1/2 respectively.
Perturbation by SGX treatment of free energy involved 
in the gating of IK(DR) was calculated as ΔΔG0 = ΔG0SGX 
−  ΔG0Ctrl  =  F(qV1/2SGX  −  qV1/2Ctrl)  =  Δ(qFV1/2), where 
ΔG0Ctrl and ΔG0SGX indicate the free energy of IK(DR) activa-
tion taken from untreated cells and cells exposed to SGX 
respectively.
The steady-state inactivation curve of IK(DR) with or 
without treatment of SGX was derived and plotted 
against the conditioning pulses and then fitted to another 
Boltzmann equation:
where V represents the conditioning potential in mV, V1/2 
is the membrane potential for half-maximal inactivation, 
and k is the slope factor of inactivation curve for IK(DR) 
elicited by membrane depolarization.
Linear or nonlinear curve-fitting to data sets presented 
herein was performed using either Microsoft Solver 
function embedded in Excel (Microsoft) or Origin 8.0 
program (OriginLab). The values are provided as the 
mean  ±  standard error of the mean (SEM) with sam-
ple sizes (n) indicating the cell number from which the 
results were obtained. The paired or unpaired Student’s 
t test and a one-way analysis of variance with the least-
significant difference method for multiple comparisons 















Table 1 Composition of normal Tyrode’s solution and the pipette solution used in this study
Solution Purpose or name Composition
Bathing solution Normal Tyrode’s solution 136.5 mM NaCl, 5.4 mM KCl, 1.8 mM CaCl2, 0.53 mM MgCl2, 5.5 mM glucose, 
and 5.5 mM HEPES–NaOH buffer, pH 7.4
Pipette solution For recordings of K+ current or membrane potential 130 mM K‑aspartate, 20 mM KCl, 1 mM KH2PO4, 1 mM MgCl2, 3 mM Na2ATP, 
0.1 mM Na2GTP, 0.1 mM EGTA, and 5 mM HEPES–KOH buffer, pH 7.2
For recordings of Na+ or Ca2+ currents 130 mM Cs‑aspartate, 20 mM CsCl, 1 mM KH2PO4, 1 mM MgCl2, 3 mM Na2ATP, 
0.1 mM Na2GTP, 0.1 mM EGTA, and 5 mM HEPES–CsOH buffer, pH 7.2
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were used for statistical evaluation of differences among 
means. Statistical analyses were performed using the Sta-
tistical Package for Social Science 20 (SPSS; IBM Corp., 
Armonk, New York). Statistical significance was deter-
mined at a P value of <0.05.
Results
Effect of SGX treatment on delayed‑rectifier K+ currents 
[IK(DR)] in differentiated NSC‑34 neuronal cells
In the first set of experiments, the whole-cell configu-
ration of the patch-clamp technique was conducted to 
investigate effects of SGX on ionic currents in these 
cells. Cells were bathed in Ca2+-free Tyrode’s solution 
that contained tetrodotoxin (1  μM) and 0.5  mM CdCl2, 
and the recording pipette was filled with K+-containing 
solution described in “Methods”. Figure  1A depicts the 
IK(DR) amplitudes when cells were exposed to different 
concentrations (10, 30 and 100 μM) of SGX. Because the 
SGX concentration at 30 μM was close to the IC50 value 
for inhibition of IK(DR), most experiments shown below 
used such concentrations. As illustrated in Fig. 1B, C, as 
the cell was held at −50  mV and different voltage steps 
ranging from −50 to +60 mV in 10-mV increments were 
applied, a family of large outward currents was readily 
elicited. Current amplitudes were increased with greater 
depolarizations in an outward-rectifying manner with a 
reversal potential of −76 ±  2  mV (n =  12). These out-
ward currents, which were insensitive to inhibition by 
either iberiotoxin (200  nM) or apamin (200  nM), have 
been referred to as IK(DR), the biophysical properties of 
which resemble the KV3.1-encoded K+ currents [12, 22]. 
In particular, as the cells were exposed to SGX (30 μM), 
the amplitude and gating of IK(DR) were altered through-
out the entire range of voltage-clamp steps as compared 
with those taken from untreated cells. For example, when 
the voltage step from −50 to +50 mV was evoked, SGX 
(10 μM) treatment significantly decreased the amplitude 
of initial IK(DR) (i.e., the 60th millisecond after the begin-
ning of voltage step) by 41  ±  3% from 1059  ±  207 to 
625 ± 167 pA (n = 11, P < 0.05). However, such treatment 
slightly but significantly decreased IK(DR) amplitude at the 
end of depolarizing pulse by 22 ± 2% from 976 ± 197 to 
766 ± 89 pA (n = 11, P < 0.05). No significant difference 
in cell capacitance between untreated (17.9  ±  1.8 pF, 
n = 13) and SGX-treated (18.1 ± 1.9 pF, n = 13, P > 0.05) 
cells could be clearly demonstrated. The averaged ampli-
tude versus voltage relationships of IK(DR) were measured 
and plotted in untreated and SGX-treated cells (Fig. 1C). 
The I–V relationships with or without SGX treatment 
were then obtained at the beginning [Fig. 1C(a)] and end 
[Fig. 1C(b)] of voltage pulses; therefore, SGX suppressed 
IK(DR) amplitude in a concentration-dependent manner. 
Additionally, neostigmine (1 μM), a typical drug used for 
reversing the effect of rocuronium-induced neuromuscu-
lar blockade, had no effect on the amplitude of gating of 
IK(DR) in these cells (Additional file 1: Fig. S1).
The activation curve of IK(DR) obtained with or 
without treatment of SGX
Figure  2 shows the activation curve of IK(DR) in the 
absence and presence of SGX (30 μM) treatment. The plot 
of relative IK(DR) amplitude as a function of membrane 
potential was determined and fitted with a Boltzmann 
function as described under “Methods”. In untreated 
cells, V1/2 = 21.1 ± 2.2 mV and q = 1.93 ± 0.04 e (n = 9), 
while in SGX-treated cells, V1/2  =  36.1  ±  1.9  mV and 
q = 2.98 ± 0.17 e (n = 9). The data showed that, as dif-
ferentiated NSC-34 cells were treated with SGX (30 μM), 
the activation curve of this current was shifted along the 
voltage axis to more positive potentials by approximately 
15 mV and the elementary charge for activation was ele-
vated 1.5-fold.
According to the values of q and V1/2, the free energy 
involved in the gating of IK(DR) at 0  mV (ΔG0) in the 
absence and presence of SGX treatment was estimated to 
be 3.93 ± 0.12 and 10.35 ± 0.18 kJ/mol (n = 9) respec-
tively. The perturbation by SGX treatment of free energy 
(ΔΔG0) involved in IK(DR) gating was calculated to be 
6.42 ± 0.15 kJ/mol. It is therefore anticipated from these 
data that SGX treatment can increase the free energy 
needed for IK(DR) activation observed in differentiated 
NSC-34 cells.
Kinetic evaluation of IK(DR) block by SGX
During cell exposure to SGX, the activation time course 
of IK(DR) in response to membrane depolarization tended 
to become slower. The activation kinetics of SGX-
induced block of IK(DR) in response to membrane depo-
larization was further quantitatively evaluated in cells 
exposed to different SGX concentrations. The concentra-
tion dependence of IK(DR) inhibition by SGX treatment 
is illustrated in Fig. 3. The results showed that its effects 
on IK(DR) could exert a concentration-dependent increase 
in the rate of development of inhibition. Consequently, 
this effect on IK(DR) in differentiated NSC-34 cells can 
be explained by a state-dependent blocking mechanism 
in which this compound may preferentially bind to the 
closed (resting) state of the KV channels according to a 
minimal kinetic scheme:
where α and β represent kinetic constants for the open-
ing and closing of the KV channel respectively; k+1 and 
k−1 are those for blocking and unblocking by SGX treat-
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indicate the closed (resting), open, and closed-blocked 
state respectively.
Blocking and unblocking rate constants, k+1 and k−1, 
could be determined from activation time constants of 
SGX-sensitive IK(DR) (i.e., difference in IK(DR) taken from 
untreated and SGX-treated cells) obtained in different 
concentrations of this compound. The rate constants 
were then computed using the relation:
Fig. 1 Effect of SGX treatment on IK(DR) in differentiated NSC‑34 neuronal cells. In these experiments, cells were bathed in Ca
2+‑free Tyrode’s solu‑
tion containing 1 μM tetrodotoxin and the recording pipette was filled with K+‑containing solution. The treated cells were incubated with SGX 
(30 μM) for 1 h at 37 °C. (A) Bar graph showing the data of IK(DR) amplitude when cells were treated with 10, 30 and 100 μM SGX. Current amplitudes 
were measured at the beginning of depolarizing voltage was obtained at the 60th milliseconds after the initial rise of voltage from −50 to +50 mV 
(mean ± SEM; n = 10–12 for each bar). *Significantly different from control (P < 0.05). (B) Superimposed current traces obtained in untreated (upper) 
and SGX‑treated (lower) cells. The cells examined were held at −50 mV and the voltages ranging from −50 to +60 mV in 10‑mV increments were 
applied, as whole‑cell recordings were established. The uppermost part indicates the voltage protocol used. (C) Current amplitude versus mem‑
brane potential relationships of IK(DR) in untreated cells (square symbols) and in cells treated with 30 μM SGX (circle symbols). In C(a) and C(b), IK(DR) 
amplitude was measured at the beginning (filled symbols) and end (open symbols) of depolarizing steps, respectively. IK(DR) amplitudes measured at 
the beginning of depolarizing voltage were obtained at the 60th milliseconds after the initial rise of voltage. Each point represents the mean ± SEM 
(n = 10–12). *Significantly different from controls [i.e., IK(DR) amplitude at the same level of voltage step] (P < 0.05)
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where k+1 and k−1 respectively resulted from the slope 
and from the y-axis intercept at [B]  =  0 of the linear 
regression interpolating the reciprocal time constants 
(1/τact) versus the SGX concentration. The relationship 
between 1/τact and [B] was computed to be linear with 
a correlation coefficient of 0.95 (Fig.  3B). The blocking 
and unblocking rate constants were thereafter calculated 
to be 0.0012  ms−1  μM−1 and 0.021  ms−1 respectively. 
According to these rate constants, dividing k−1 by k+1 
yielded a dissociation constant (KD) of 17.5  μM under 
SGX treatment.
Inability of SGX to modify the steady‑state inactivation 
curve of IK(DR)
In order to further characterize effect of SGX treat-
ment on IK(DR), we next studied the inactivation of IK(DR) 
in differentiated cells using a two-step voltage proto-
col. The quasi-inactivation curves of IK(DR) in untreated 
and SGX-treated cells are illustrated in Fig.  4. In this 
set of experiments, a 10-s conditioning pulse in dif-
ferent membrane potentials preceded a test potential 
(300 ms in duration) to +80 mV from a holding poten-
tial of −90  mV (Fig.  4a). The relationships between the 
conditioning pulses and the normalized amplitudes 
of IK(DR) in untreated and SGX-treated cells were con-
structed and fitted by the Boltzmann equation described 
in “Methods”. In untreated cells, V1/2 = 6.2 ± 0.9 mV and 




V1/2 = 6.3 ± 0.09 mV and k = 0.44 ± 0.03 mV (n = 9). 
Distinguishable from the results of IK(DR) activation curve 
obtained in untreated and SGX-treated cells, the values 
for both V1/2 and k were not found to differ significantly 
between the two groups of cells (P  >  0.05). The experi-
mental results therefore suggest that there is little or no 
modification in the voltage-dependent profile of IK(DR) 
inactivation following SGX treatment.
The increase of cumulative inhibition of IK(DR) activation 
in SGX‑treated cells
In another set of experiments, we sought to deter-
mine whether in SGX-treated cells, the activation time 
course of IK(DR) induced by repetitive depolarizing 
stimuli could be altered. Under control conditions (i.e., 
in untreated cells), a single 100-ms depolarizing step 
to +50  mV from a holding potential of −50  mV was 
applied to produce an exponential increase of IK(DR) 
with a time constant of 27 ± 2 ms (n = 10). However, 
the activation time constant for 10-ms repetitive pulses 
to +50 mV, each of which lasted 10 ms with 5-ms inter-
val at −50  mV between the depolarizing pulses, was 
significantly reduced to 19 ±  2 ms (n =  10, P < 0.05). 
The results indicate a progressive increase in the activa-
tion rate of IK(DR) in response to repetitive depolarizing 
stimuli (Fig. 5 and Additional file 2: Fig. S2). However, 
in SGX-treated cells, the value of activation time con-
stant obtained during this train of short repetitive 
pulses became raised. In the cells exposed to 30  μM 
SGX, the time constants were significantly increased 
to 47 ± 5 ms (n = 9, P < 0.05); accordingly, the results 
showed that there was an excessive accumulative slow-
ing in the activation of IK(DR) as cells were exposed to 
SGX.
Effect of SGX treatment on voltage‑gated Na+ current (INa) 
in differentiated NSC‑34 cells
In the next set of experiments, we investigated effect of 
SGX treatment on INa in these cells. Untreated or SGX-
treated cells were bathed in Ca2+-free Tyrode’s solution 
containing 10  mM TEA and the recording pipette was 
filled with Cs+-containing solution, the composition of 
which is shown in Table 1. The INa was elicited by depo-
larizing pulse from −80 to −10  mV with a duration of 
100 ms. In our experiments, SGX treatment at 10, 30, and 
100  μM did not exert any significant effect on the peak 
amplitude of INa or ICa,L in these cells. As shown in Fig. 6, 
there was no significant difference in the amplitude of 
INa between untreated cells (1.82 ±  0.3 nA, n =  8) and 
cells treated with SGX (10  μM) (1.81 ±  0.2 nA, n =  8, 
P  >  0.05). However, in SGX-treated cells, addition of 
ranolazine (10 μM), a blocker of INa [27], was capable of 
suppressing the peak amplitude of INa significantly from 
Fig. 2 Effect of SGX on the activation curve of IK(DR) recorded from 
differentiated NSC‑34 neuronal cells. In these experiments, cells were 
bathed in Ca2+‑free Tyrode’s solution. Voltage dependence of IK(DR) 
activation in the absence (filled square symbol) and presence (open 
square symbol) of SGX (30 μM) treatment (mean ± SEM; n = 9 for 
each point) is illustrated. The smooth lines obtained in untreated and 
SGX‑treated cells represent the best fits to the Boltzmann equation 
described in “Methods”. Notably, SGX treatment can shift the activa‑
tion curve of IK(DR) to a depolarizing voltage, together with increase in 
the gating charge of this current
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1.82 ± 0.2 nA to 0.98 ± 0.1 nA (n = 7, P < 0.05). There-
fore, SGX treatment per se did not modify the amplitude 
of INa in these cells, while the presence of ranolazine 
remained effective at suppressing INa in SGX-treated 
cells.
Comparison of the effect of dexamethasone (DEX) 
on L‑type Ca2+ current (ICa,L) in SGX‑treated cells
SGX is a modified γ-cyclodextrin and able to encapsulate 
steroid-like compounds [1, 4]. DEX, a synthetic glucocor-
ticoid, can produce an inhibitory effect on the reversal 
of rocuronium-induced neuromuscular block by SGX in 
functionally innervated human muscle cells [28]. There-
fore, in a final set of experiments, it was further examined 
whether the amplitude of ICa,L recorded from SGX-
treated cells could be altered by DEX. The experiments 
were performed as cells were bathed in normal Tyrode’s 
solution containing 1.8  mM CaCl2 and 1  μM tetrodo-
toxin, and the recording pipette was filled with Cs+-con-
taining solution. The peak amplitude of ICa,L in response 
to membrane depolarization from −50 to 0 mV was effec-
tively suppressed by the presence of nifedipine (1 μM), a 
blocker of ICa,L, but not by ω-conotoxin GVIA (1  μM), 
a toxin isolated from Conus geographus and known to 
block N-type Ca2+ current (Additional file 3: Fig. S3). As 
illustrated in Fig.  7, as untreated cells were depolarized 
from −50 to 0 mV, DEX (30 μM) significantly suppressed 
the peak amplitude of ICa,L from 51.7 ± 5.3 to 24.5 ± 2.6 
pA (n = 11, P < 0.05); however, the overall I–V relation-
ship of this current remained unchanged in the presence 
of DEX. The concentration of DEX (30 μM) used in this 
study was fundamentally based on a previous report 
[29]. The results are compatible with previous observa-
tions made in pituitary tumor cells [29]. In contrast, in 
SGX-treated cells, DEX at the same concentration had no 
significant effect on the amplitude of ICa,L [52.1 ± 5.3 pA 
(control), n = 11 versus 51.9 ± 5.4 pA (in the presence of 
DEX), n =  11, P  >  0.05]; therefore, findings from these 
Fig. 3 Evaluation of the kinetics of SGX‑induced block of IK(DR). The 
IK(DR) established by depolarizing pulses from −50 to +50 mV was 
measured with cell treatment of different SGX concentrations. In A, 
activation time courses of SGX‑sensitive IK(DR) (τact) obtained during 
cell exposure to 10 μM (a) and 30 μM (b) SGX were fitted by a single 
exponential with a value of 27.1 and 15.9 ms respectively. SGX‑
sensitive current was taken by subtracting current in SGX‑treated 
cells from that in untreated ones. In B, the reciprocal of activation 
time constant (i.e., 1/τact) of SGX‑sensitive current was plotted against 
the SGX concentration. Data points shown in open circles were well 
fitted by a linear regression, indicating that there is a molecularity of 
one. According to reaction scheme, blocking (k+1) and unblocking 
(k−1) rate constants for SGX‑induced blocks of IK(DR) were calculated 
to be 0.0012 ms−1 μM−1 and 0.021 ms−1 respectively. Mean ± SEM 
(n = 8–11 for each point)
Fig. 4 Steady‑state inactivation of IK(DR) obtained in the absence and 
presence of SGX treatment. With the aid of a two‑step voltage proto‑
col, the steady‑state inactivation parameters of IK(DR) in differentiated 
NSC‑34 cells were evaluated. a Superimposed current traces obtained 
in an untreated cell. Inset in a indicates the voltage protocol used 
in this set of experiments. b Normalized amplitudes of IK(DR) (I/Imax) 
obtained in the control (filled square symbol) and during cell exposure 
to 30 μM SGX (open square symbol) were constructed against the con‑
ditioning potential. The smooth curves derived from untreated and 
SGX‑treated cells were fitted by the Boltzmann equation as described 
in “Methods”. Each point represents the mean ± SEM (n = 9)
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results indicate that, in SGX-treated cells, DEX-mediated 
inhibition of ICa,L in response to membrane depolariza-
tion was abolished.
Discussion
In this study, the blocking of IK(DR) by SGX treatment 
was noted to be not instantaneous, but to develop with 
time immediately after the cell became depolarized. 
Such treatment produces a time-dependent increase 
in the activation time constant of IK(DR) in response to 
membrane depolarization. However, the inactivation 
curve of IK(DR) obtained in untreated and SGX-treated 
cells did not differ significantly. It thus appears that, as 
cells are exposed to SGX, this compound has a greater 
affinity for the closed (resting) state in the KV channel 
existing on differentiated NSC-34 cells. The activated 
channels during SGX treatment tended to produce a 
lower affinity than those residing in the closed state. 
As a result, the transition from closed to open state 
became slowed during cell exposure to SGX. Based on 
our study, it is therefore tempting to speculate that the 
treatment of SGX or other structurally similar agents 
binds to the closed state of the channel and/or blocks 
a prolonged channel closing in KV3.1 channels. Alter-
natively, the challenge of cells with SGX or other struc-
turally similar agents can modulate KV3.1 channels 
where the closed channel conformation represents the 
high-affinity binding site. It also needs to be noted that, 
according to minimal reaction scheme shown here, the 
dissociation constant for SGX treatment was calculated 
to be 17.5 μM, a value that can be clinically achievable 
[1, 3, 5].
The KV3.1-encoded currents were reported to be the 
major molecular components of IK(DR) in these cells [20, 
21]. Importantly, our study demonstrated that the acti-
vation kinetics of IK(DR) (i.e., KV3.1-encoded current) 
in SGX-treated cells virtually became slowed in a time- 
and state-dependent manner. The results were in con-
trast with inhibitory effects of midazolam or aconitine 
on IK(DR) [12, 21]. These two compounds exerted inhibi-
tory effects via a mechanism through binding to the open 
state of the channel followed by increased rate of IK(DR) 
inactivation. During repetitive stimuli, the perturbation 
by SGX treatment of IK(DR) activation was potentiated.
By virtue of computational analysis, previous work 
has shown that changes in activation kinetics of IK(DR) 
might lead to generation of action potentials with spike-
frequency adaptation [23]. The ability of KV3.1-encoded 
currents to control the waveforms of action potentials at 
synapses has recently been reported [16]. Indeed, differ-
ent de novo mutations in KCNC1 have been reported to 
display a wide variety of progressive myoclonus epilepsy 
[17]. However, SGX treatment had little or no effect on 
Fig. 5 Time course of repetitive cumulative activation of IK(DR) 
obtained with or without SGX treatment. In A, the peak amplitude of 
each IK(DR) was measured during repetitive depolarizations from −50 
to +50 mV with a duration of 10 ms at a rate of 70 Hz. Filled and open 
circles were obtained in untreated and SGX‑treated cells respectively. 
Inset indicates the voltage protocol used. In B, original IK(DR) traces (a 
and b) in response to rapid membrane depolarization from −50 to 
+50 mV were shown. Traces a and b correspond to the data points 
labeled a and b in A. Arrowhead in traces a and b indicate the zero 
current level. Notably, in addition to inhibition of IK(DR) amplitude, SGX 
treatment can slow the rate of excessive cumulative activation of IK(DR) 
in response to repetitive stimuli. *Significantly different from the data 
from untreated cells (P < 0.05). Mean ± SEM (n = 9–10)
Fig. 6 Effect of SGX treatment on voltage‑gated Na+ current (INa) in 
differentiated NSC‑34 cells. The untreated and SGX‑treated cells were 
bathed in Ca2+‑free Tyrode’s solution. INa was evoked in response to 
membrane depolarization from −80 to −10 mV. a Superimposed INa 
tracings obtained in the cell without (a) and with (b) the exposure 
to SGX (30 μM). INa trace labeled (c) was obtained after addition 
of ranolazine (10 μM) in SGX‑treated cells. The inset indicates an 
expanded record from dashed box. Notably, INa amplitude obtained 
from untreated and SGX‑treated cells did not differ significantly; 
however, ranolazine could effectively suppress INa recorded from 
SGX‑treated cells
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the peak amplitude of INa. Therefore, the present results 
showing any changes in the amplitude and gating by SGX 
treatment of IK(DR) can be of pharmacological and clinical 
relevance.
Following SGX treatment, IK(DR) enriched in differenti-
ated NSC-34 cells became activated at more depolarized 
voltages in comparison with that from untreated cells. 
Moreover, the steepness of activation curve for IK(DR) 
became significantly greater in cells exposed to SGX, indi-
cating that the effective number of elementary charges 
during channel activation in SGX-treated cells was sig-
nificantly raised. These results are important because they 
led us to estimate that energy change (ΔG0SGX) for genera-
tion of IK(DR) was a value of 10.35 kJ/mol. This value was 
found to be significantly greater than that ΔG0Ctrl (i.e., 
3.93 kJ/mol) in untreated cells. SGX treatment apparently 
is involved in voltage-sensitive gating functions of IK(DR), 
despite no clear change in inactivation curve of IK(DR) 
between the two groups of cells. The results lead us to 
propose that following SGX treatment, the energy barrier 
for activation of KV3.1 channels became elevated.
In our experimental conditions, supplementation of 
the medium with retinoic acid resulted in changes in cell 
morphology and an increase in mRNA expression of the 
KV3.1 subunit in differentiated NSC-34 neuronal cells [20, 
21]. However, the modification of IK(DR) kinetics by SGX 
presented here did not appear to occur by the gene regula-
tion of these channels, because significant changes in this 
current in differentiated NSC-34 cells generally occurred 
with a short time course. Moreover, no changes in IK(DR) 
density after treatment with SGX were observed, suggest-
ing that such maneuver did not alter the main parts of ion 
channel permeation pathway (i.e., the S5 and S6 regions). 
It is thus possible that SGX treatment can regulate the 
gating kinetics of IK(DR) with no apparent change in the 
number of functional channels on plasma membrane.
Consistent with previous studies [29], we clearly demon-
strated that addition of DEX suppressed the peak ampli-
tude of ICa,L in differentiated NSC-34 neuronal cells. It is 
important to note, however, that the inhibition by DEX of 
ICa,L did not occur in SGX-treated cells, despite the ability 
of MgSO4 to suppress ICa,L amplitude in both untreated 
and SGX-treated cells (data not shown). Previous obser-
vations have shown that DEX did not increase the activity 
of large-conductance Ca2+-activated K+ (BKCa) channels 
in pituitary cells treated with methyl-β-cyclodextrin [30], 
Fig. 7 Effect of DEX on L‑type Ca2+ current (ICa,L) in untreated and SGX‑treated cells. In these experiments, cells were bathed in normal Tyrode’s 
solution containing 1.8 mM CaCl2 and the recording pipette was filled with Cs
+‑containing solution. In the upper parts of a and b, superimposed 
ICa,L traces were obtained in untreated cells respectively. ICa,L traces labeled a in each panel are controls (i.e., in the absence of DEX) and those 
labeled b were obtained after addition of 30 μM DEX. Inset in the upper part of each panel indicates the voltage protocol used. Bar graphs shown in 
each panel indicate the summary of data showing inhibitory effect of DEX on the peak amplitude of ICa,L in untreated (A) and SGX‑treated (B) cells 
(mean ± SEM; n = 11 for each bar). *Significantly different from control (P < 0.05). DEX: 30 μM dexamethasone
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suggesting that the binding of DEX to the protein(s) of 
BKCa channels relies on membrane cholesterol.
Whether DEX produces any significant effect on INa or 
IK(DR) in NSC-34 cells or primary motor neurons needs 
to be further investigated. Whether the presence of SGX 
alters the cholesterol content in surface membranes and 
influences the DEX effect on ICa,L also remains to be 
explored. Nonetheless, our experimental results are con-
sistent with earlier work showing that DEX is effective 
at exerting inhibitory effects on SGX reversal of rocuro-
nium-induced neuromuscular block [28]. Alternatively, 
removal by SGX of DEX-induced block of ICa,L could be 
due mostly to the possibility that, similar to a mechanism 
by which it can reverse muscle relaxing effects by rocuro-
nium, the SGX molecule can effectively encapsulate the 
DEX molecule [1, 3–5].
A recent report showed that methyl-β-cyclodextrin, 
a cholesterol-depleting agent, could induce activation 
of matrix metalloproteinase-2 (MMP-2) [31]. However, 
the reduction by SGX treatment of IK(DR) activation rate 
observed in differentiated NSC-34 cells was unable to 
be reversed by isobavachalcone (10 μM) known to be an 
inhibitor of MMP-2 activity [32]. Therefore, alterations 
by SGX treatment of activation kinetics of IK(DR) observed 
in differentiated NSC-34 cells are not closely associated 
with a mechanism linked to MMP-2 activation.
It should be noted that the pipette solution used in 
this study contained 3  mM ATP, which can adequately 
suppress the activity of ATP-sensitive K+ (KATP) chan-
nels. The activity of KATP channels did not differ between 
the untreated and SGX-treated cells (data not shown). 
Changes by SGX treatment of IK(DR) amplitude and gat-
ing observed in differentiated NSC-34 cells is unlikely to 
arise from inhibition of KATP channels.
The observed block of IK(DR) caused by SGX treatment 
actually provides an intriguing mechanism for its inhibi-
tion that relies on the closed (resting) state of the KV3.1-
encoded channels. The KV3.1-encoded currents were 
enriched in many central neurons including hippocampal 
pyramidal neurons, auditory neurons, and Purkinje cells [9, 
11, 13, 14]. The activity of these KV channels is recognized 
as participating in electrical behaviors of fast-spiking neu-
rons [9, 10, 15, 16]. Challenging cells with SGX reduced the 
amplitude of IK(DR) and slowed the activation time course 
of this current recorded from differentiated NSC-34 cells as 
well. The present observations would clearly initiate further 
studies to understand the SGX effects on electrical activ-
ity of motor neurons. Whether SGX-induced reversal of 
rocuronium-induced neuromuscular blockade is due partly 
to its blocking of IK(DR) in motor neurons in vivo remains to 
be further investigated. Some adverse effect such as move-
ment of a limb or the body may be partly explained by its 
inhibitory effect on IK(DR).
It is noted that neostigmine, an inhibitor of acetylcho-
linesterase activity, is a typical drug used in anesthesia 
for reversing the effect of rocuronium-induced neuro-
muscular blockade. In our study, neostigmine (1 μM) did 
not exert any effect on the amplitude and gating of IK(DR) 
in differentiated NSC-34 cells (Additional file 1: Fig. S1). 
Findings from our study might explain previous observa-
tions showing that SGX could reverse more rapidly rocu-
ronium-induced neuromuscular blockade [33] or that the 
treatment with SGX was associated with less frequent 
dry mouth than that of neostigmine [34]. Therefore, it 
remains to be further delineated whether SGX might 
exert differential actions when it is used with patients 
who have been administrated with DEX or other gluco-
corticoids [4], if similar findings presented here occur 
in  vivo. Nonetheless, as motor neurons are exposed to 
SGX, the amplitude and gating of IK(DR) could be modi-
fied and these actions might significantly contribute to 
functional activities of motor neurons.
Conclusion
The SGX treatment may influence the amplitude and gating 
of IK(DR) and its actions could contribute to functional activi-
ties of motor neurons if similar findings occurred in vivo.
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